Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 7/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | CCR4 | P51679 | 4/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652464 | 0.86 | KAT6A (0.47) | KAT6A | |
| SCHEMBL21641914 | 0.86 | KAT6A (0.47) | KAT6A | |
| SCHEMBL21609115 | 0.84 | MEN1 (0.55) | SLC40A1ATMMEN1KMT2A | |
| SCHEMBL21609121 | 0.78 | EDNRA (0.50) | BRD4CCR4EDNRBEDNRAKAT6A | |
| SCHEMBL21609081 | 0.78 | CCKBR (0.42) | SLC40A1MEN1KMT2ABRD4CCR4 | |
| SCHEMBL21609018 | 0.76 | KMT2A (0.52) | MEN1KMT2A | |
| SCHEMBL21609022 | 0.76 | HTR2A (0.44) | BRD4EDNRBEDNRA | |
| SCHEMBL21609028 | 0.76 | BRD4 (0.41) | SLC40A1MEN1KMT2ABRD4CCR4 | |
| SCHEMBL21609217 | 0.76 | EDNRB (0.46) | SLC40A1MEN1KMT2AEDNRBEDNRA | |
| SCHEMBL29652497 | 0.76 | EDNRB (0.46) | SLC40A1MEN1KMT2AEDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | SLC40A1 459/4885ATM 3790/4885MEN1 122/4885 |
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | SLC40A1 460/4885ATM 3790/4885MEN1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.